Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Jeanette K Doorduijn"'
Autor:
Lina van derStraten, Mark‐David Levin, Manette A. W. Dinnessen, Otto Visser, Eduardus F. M. Posthuma, Jeanette K. Doorduijn, Anton W. Langerak, Arnon P. Kater, Avinash G. Dinmohamed
Publikováno v:
HemaSphere, Vol 8, Iss 11, Pp n/a-n/a (2024)
Abstract Chronic lymphocytic leukemia (CLL) manifests heterogeneously with varying outcomes. This population‐based study examined causes of death (CODs), as registered by the physician who established the death, among 20,588 CLL patients diagnosed
Externí odkaz:
https://doaj.org/article/69e8af3064e9466f885ecb842801b1fa
Autor:
Lennert Slobbe, Jeanette K Doorduijn, Pieternella J Lugtenburg, Abdelilah El Barzouhi, Eric Boersma, Willem B van Leeuwen, Bart J A Rijnders
Publikováno v:
PLoS ONE, Vol 5, Iss 5, p e10840 (2010)
Catheter-related bloodstream infection (CRBSI) results in significant attributable morbidity and mortality. In this randomized, double-blind, placebo-controlled trial, we studied the efficacy and safety of a daily ethanol lock for the prevention of C
Externí odkaz:
https://doaj.org/article/bc9378a4464d40cd93702c1418ac4145
Autor:
Andrés J. M. Ferreri, Gerald Illerhaus, Jeanette K. Doorduijn, Dorothee P. Auer, Jacoline E. C. Bromberg, Teresa Calimeri, Kate Cwynarski, Christopher P. Fox, Khê Hoang‐Xuan, Denis Malaise, Maurilio Ponzoni, Elisabeth Schorb, Carole Soussain, Lena Specht, Emanuele Zucca, Christian Buske, Mats Jerkeman, Martin Dreyling, EHA and ESMO Guidelines Committees
Publikováno v:
HemaSphere, Vol 8, Iss 6, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/807b45d1901f4a1fb725d65cf1a58ec3
Autor:
Lina van der Straten, Mark-David Levin, Manette A. W. Dinnessen, Otto Visser, Eduardus F. M. Posthuma, Jeanette K. Doorduijn, Anton W. Langerak, Arnon P. Kater, Avinash G. Dinmohamed
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract The longevity of patients with chronic lymphocytic leukemia (CLL) has improved progressively over the past decades, making it essential to understand long-term health outcomes, such as second primary malignancies (SPMs). Therefore, this nati
Externí odkaz:
https://doaj.org/article/fe5a21bbbb564ebc86aae6de741eef1b
Autor:
Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, Pier Luigi Zinzani, Andre Goy, Stephen D. Smith, Jeanette K. Doorduijn, Carlos Panizo, Bijal D. Shah, Andrew J. Davies, Richard Eek, Eric Jacobsen, Arnon P. Kater, Tadeusz Robak, Preetesh Jain, Roser Calvo, Lin Tao, Michael Wang
Publikováno v:
Haematologica, Vol 109, Iss 1 (2023)
Externí odkaz:
https://doaj.org/article/c4917574fe414e708d9135d90b9b085d
Autor:
Lina van der Straten, Carolien C. H. M. Maas, Mark-David Levin, Otto Visser, Eduardus F. M. Posthuma, Jeanette K. Doorduijn, Anton W. Langerak, Arnon P. Kater, Avinash G. Dinmohamed
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/4ed256459b644cceb441958cdf77ea39
Autor:
Lina van derStraten, Mark‐David Levin, Otto Visser, Eduardus F.M. Posthuma, Jeanette K. Doorduijn, Arnon P. Kater, Avinash G. Dinmohamed
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 180-183 (2022)
Abstract Studies on conditional relative survival (CRS) in chronic lymphocytic leukaemia (CLL) have hitherto been lacking in the literature. We predicted up‐to‐date estimates of 5‐year RS at diagnosis and for each additional year survived (i.e.
Externí odkaz:
https://doaj.org/article/ce70bef7dc80455c8bc646e21253a404
Autor:
Matthijs van der Meulen, Jacoline E.C. Bromberg, Marcel Nijland, Otto Visser, Jeanette K. Doorduijn, Avinash G. Dinmohamed
Publikováno v:
Haematologica, Vol 106, Iss 2 (2020)
Externí odkaz:
https://doaj.org/article/98aea889c6f84dd6af99ebce2617614a
Autor:
Doreen G Te, Raa, Lina, van der Straten, Michel, van Gelder, Sabina, Kersting, Mark-David, Levin, Rogier, Mous, Hanneke M, van der Straaten, Marten R, Nijziel, Ellen, van der Spek, Eduardus F M, Posthuma, Hein P J, Visser, Marjolein, van der Klift, Koen, de Heer, Mar, Bellido, Jeanette K, Doorduijn, Anke H W, Bruns, Reinier A P, Raijmakers, Arnon P, Kater
Publikováno v:
HOVON CLL study group 2022, ' Diagnosis, treatment and supportive management of chronic lymphocytic leukemia : recommendations of the Dutch HOVON CLL working group ', Leukemia and Lymphoma, vol. 63, no. 10, pp. 2276-2289 . https://doi.org/10.1080/10428194.2022.2084731
Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfc5ffe46d9de15522c014f7cbb5f7ef
https://hdl.handle.net/11370/29686129-bbf3-41c9-8726-fd23f290d6e6
https://hdl.handle.net/11370/29686129-bbf3-41c9-8726-fd23f290d6e6
Autor:
Arnon P. Kater, Marinus H.J. van Oers, Yvette van Norden, Lina van der Straten, Julia Driessen, Ward F.M. Posthuma, Martin Schipperus, Martine E.D. Chamuleau, Marcel Nijland, Jeanette K. Doorduijn, Michel Van Gelder, Mels Hoogendoorn, Francien De Croon, Shulamiet Wittebol, J. Martijn Kerst, Erik W.A. Marijt, Reinier A.P. Raymakers, Martijn R. Schaafsma, Johan A. Dobber, Sabina Kersting, Mark-David Levin
Publikováno v:
Haematologica, Vol 104, Iss 1 (2019)
Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to ev
Externí odkaz:
https://doaj.org/article/fd2f85f1135842ee993a2e9b722ce63a